Ban on manufacture and sale of fixed dose combinations
Sanofi India Ltd has informed BSE regarding "Ban on manufacture and sale of fixed dose combinations."23-03-2016
23-03-2016
Sanofi pledges stable 2016 earnings despite Q4 decline
In France, the company is considering a voluntary early retirement plan that could lead to about 600 job cuts over three years.09-02-2016
Sanofi India Q4 Net Profit Rises 30% to Rs 120 Crore
In a separate filing, Sanofi India said its Board has recommended a final dividend of Rs 25 per equity share of Rs 10 for the year ended December 31, 2015. An interim dividend of Rs 18 per equity shar...04-02-2016
Board recommend Final Dividend, Special One-time Dividend & Special One-time Diamond Jubilee Dividend
Sanofi India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 04, 2016, inter alia, has recommended:1. Final dividend of Rs. 25 per Equity share of Rs. 10 for the year ended December 31, 2015. An Interim dividend of Rs. 18 per Equity Share of Rs. 10 had been paid in August 2015.2. A Special One-time dividend of Rs. 14 per Equity share of Rs.10 arising from the profit on the sale of the Company's commercial premises in Mumbai....04-02-2016
Announces Q4 & FY15 Results (Standalone), Form A (Standalone) & Auditors' Report (Standalone) for the period ended December 31, 2015
Sanofi India Ltd has announced the following results for the quarter & year ended December 31, 2015 The Audited Standalone results for the Quarter ended December 31, 2015:The Company has posted a net profit after exceptional items of Rs. 1202 million for the quarter ended December 31, 2015 as compared to Rs. 925 million for the quarter ended December 31, 2014. Total Income has increased from Rs. 5271 million for the quarter ended...04-02-2016
Sanofi launches R&D; for vaccine against Zika virus
WHO on Monday declared a health emergency as the virus infection spread to more than 20 countries in the Americas since 201502-02-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015
Sanofi India Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.28-01-2016
Shareholding for the Period Ended December 31, 2015
Sanofi India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2015. For more details, kindly Click here25-01-2016
FY15 results on Feb 04, 2016
Sanofi India Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 04, 2016 for approving the audited accounts for the year ended December 31, 2015 and also to consider recommendation of final dividend for the said financial year.20-01-2016